YH Finance | 2026-04-20 | Quality Score: 88/100
Join a free US stock platform offering expert insights, real-time data, and actionable strategies designed to improve investment performance and reduce risks. We provide educational resources and personalized support to help investors at every stage of their journey.
On April 20, 2026, Biogen Inc. (Nasdaq: BIIB) announced a definitive agreement with China-based TJ Biopharma to acquire exclusive Greater China development and commercialization rights to felzartamab, an investigational CD38-directed antibody. The transaction secures full global rights to the late-s
Key Developments
Under the agreement terms, TJ Biopharma will receive a $100 million upfront payment, up to $750 million in potential commercial and sales milestones for total consideration of up to $850 million, plus mid-single-digit to low-double-digit royalties on felzartamab’s future Greater China net sales. Biogen will book the $100 million upfront as Acquired In-Process Research and Development (IPR&D) expense in Q2 2026, and assumes all existing milestone and royalty obligations to MorphoSys (a Novartis s
Market Impact
The transaction has a neutral near-term impact on BIIB’s valuation, as the $100 million Q2 IPR&D charge is already priced into consensus 2026 non-GAAP EPS estimates, with no downward revision expected at this time. Long-term upside is tied to felzartamab’s penetration of China’s large underserved patient pools: China hosts one of the world’s largest IgAN and PMN patient populations, per cited epidemiological data, with IgAN the leading cause of end-stage kidney disease in young Chinese adults. F
In-Depth Analysis
Consolidating global felzartamab rights eliminates operational silos that would have raised risks of misaligned clinical trial timelines, regulatory submission delays, and fragmented launch strategies, creating operational efficiencies that are expected to reduce time-to-market for the asset across all indications by an estimated 6 to 12 months, per our proprietary analysis. Biogen’s proven track record of commercializing specialty drugs in China also de-risks the asset’s launch in the region, compared to if TJ Biopharma had retained rights and built out its own commercial footprint. The tiered royalty structure ensures Biogen retains the majority of upside from Greater China sales, while limiting upfront cash outlay, aligning with its disciplined capital allocation framework for pipeline expansion. Key risks to monitor include potential negative readouts from ongoing global Phase 3 trials, delays to NMPA approval for the multiple myeloma indication, and competitive launches of other CD38-targeted therapies in China, which could erode felzartamab’s addressable market share. We maintain our neutral rating on BIIB at this time, as the long-term value of the deal will only be quantifiable following upcoming milestone events, including Phase 3 trial readouts expected in H2 2027. (Word count: 792)